Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires $179,629.06 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 32,134 shares of the stock in a transaction on Wednesday, August 19th. The shares were purchased at an average cost of $5.59 per share, for a total transaction of $179,629.06. Following the acquisition, the chief executive officer directly owned 32,134 shares of the company’s stock, valued at approximately $179,629.06. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

KindlyMD Stock Performance

Shares of KindlyMD stock opened at $7.06 on Monday. The company has a fifty day moving average of $4.54 and a 200 day moving average of $7.19. KindlyMD, Inc. has a fifty-two week low of $3.33 and a fifty-two week high of $422.40. The company has a market capitalization of $126.37 million, a P/E ratio of -0.20 and a beta of 15.94.

KindlyMD (NASDAQ:NAKA) last released its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. The business had revenue of $35.87 million for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. Analysts forecast that KindlyMD, Inc. will post -11.31 EPS for the current year.

Trending Headlines about KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. TD Cowen boosted their target price on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, KindlyMD has a consensus rating of “Hold” and a consensus price target of $22.33.

Institutional Trading of KindlyMD

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in KindlyMD in the fourth quarter worth about $151,000. J. Derek Lewis & Associates Inc. purchased a new stake in KindlyMD during the fourth quarter valued at approximately $167,000. Truist Financial Corp purchased a new stake in KindlyMD during the fourth quarter valued at approximately $176,000. Waddell & Associates LLC bought a new position in shares of KindlyMD during the 4th quarter valued at approximately $201,000. Finally, Invesco Ltd. bought a new stake in KindlyMD in the fourth quarter worth $211,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.